5 completed, 2 unknown, 1 active not recruiting, 1 not yet recruiting. 9 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 5, Unknown 2, Active not recruiting 1, Not yet recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow Acute Pyelonephritis: new trials by email Literature Review of Acute Pyelonephritis trials Research Report on Acute Pyelonephritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| This is a Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ertapenem-zidebactam Versus Ceftazidime-Avibactam in the Treatment of Hospitalized Adult Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis Ertapenem-zidebactam, Ceftazidime-Avibactam, Ertapenam-Zidebactam - Complicated Urinary Tract Infections(cUTI), Acute Pyelonephritis | Phase 2 | Not yet recruiting | Wockhardt | 279 | 2026-09-30 | 2026-09-24 |
| A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis Meropenem-Vaborbactam, Antibiotics - Acute Pyelonephritis, Complicated Urinary Tract Infection | Phase 2 | Active not recruiting | Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC) | 66 | 2025-06-03 | 2026-09-10 |
| Meropenem-FL058 Phase 2 Study in the Treatment of Complicated Urinary Tract Infections Meropenem- FL058, Piperacillin -tazobactam, Saline - Complicated Urinary Tract Infection, Acute Pyelonephritis | Phase 2 | Unknown | Qilu Pharmaceutical Co., Ltd. | 150 | 2021-10-08 | 2021-09-29 |
| IV or IV/PO Omadacycline vs. IV/PO Levofloxacin for the Treatment of Acute Pyelonephritis Omadacycline, Levofloxacin - Acute Pyelonephritis | Phase 2 | Completed | Paratek Pharmaceuticals Inc | 201 | 2018-11-19 | 2020-07-07 |
| Evaluation of Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract Infections Sulbactam-ETX2514, Placebo, Imipenem-cilastatin - Complicated Urinary Tract Infection, Acute Pyelonephritis | Phase 2 | Completed | Entasis Therapeutics | 80 | 2018-01-17 | 2020-01-22 |
| Safety and Efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections ZTI-01, Piperacillin-tazobactam - Urinary Tract Infection Symptomatic, Acute Pyelonephritis | Phase 2 / Phase 3 | Completed | Nabriva Therapeutics AG | 465 | 2016-04-01 | 2019-03-07 |
| Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis Finafloxacin 800 mg i.v. once daily, Finafloxacin placebo i.v. once daily, Finafloxacin 800 mg tablets once daily - Urinary Tract Infections, Acute Pyelonephritis | Phase 2 | Completed | MerLion Pharmaceuticals GmbH | 225 | 2012-12-01 | 2017-06-20 |
| Sitafloxacin and Ertapenem Treatment for Acute Pyelonephritis Caused by Escherichia Coli Sitafloxacin, Ertapenem - Infection Due to Escherichia Coli, Acute Pyelonephritis | Phase 2 | Unknown | Mahidol University | 96 | 2012-11-01 | 2015-09-02 |
| A Study of Plazomicin Compared With Levofloxacin for the Treatment of Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP) levofloxacin, plazomicin, placebo - Complicated Urinary Tract Infection, Acute Pyelonephritis | Phase 2 | Completed | Achaogen, Inc. | 145 | 2010-07-13 | 2018-08-22 |
Pyelonephritis (2) · Urinary Tract Infections (2) · Escherichia coli Infections (1)
Infections (3) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Kidney Diseases (2) · Male Urogenital Diseases (2) · Nephritis (2) · Nephritis, Interstitial (2) · Pyelitis (2) · Urogenital Diseases (2) · Urologic Diseases (2) · Bacterial Infections (1) · Bacterial Infections and Mycoses (1) · Enterobacteriaceae Infections (1) · Gram-Negative Bacterial Infections (1)
Levofloxacin (2) · Piperacillin, Tazobactam Drug Combination (2) · Sodium Chloride (2) · Anti-Bacterial Agents (1) · Carbapenems (1) · Cilastatin, Imipenem Drug Combination (1) · Ciprofloxacin (1) · Ertapenem (1) · Fluoroquinolones (1) · avibactam, ceftazidime drug combination (1) · finafloxacin (1) · meropenem and vaborbactam (1) · omadacycline (1) · plazomicin (1) · sitafloxacin (1)
Achaogen, Inc. (1) · Entasis Therapeutics (1) · Mahidol University (1) · MerLion Pharmaceuticals GmbH (1) · Nabriva Therapeutics AG (1) · Paratek Pharmaceuticals Inc (1) · Qilu Pharmaceutical Co., Ltd. (1) · Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC) (1) · Wockhardt (1)
Bulgaria (3) · Georgia (3) · Croatia (2) · Greece (2) · Latvia (2) · Poland (2) · Russia (2) · Ukraine (2) · United States (2) · Belarus (1) · Czechia (1) · Estonia (1) · Germany (1) · Hungary (1) · India (1)
Anibal Calmaggi, MD (1) · Evelyn J Ellis-Grosse, PhD (1) · Florian Wagenlehner, Prof. (1) · Huang Haihui, Professor (1) · Michal Nowicki, Prof. (1) · Sasisopin Kiertiburanakul (1)
PMID 29339393, PMID 29339394, PMID 29339395, PMID 30861061, PMID 31843995
2015 (1)